Delcath Systems (DCTH)

Will have an FDA decision in July. Whether they get approval or not, there will be a huge move up or down. Options strategy? Market knows this is going to have an impact so this gets priced into the options. Very difficult to do this.

Liver cancer treatment. They isolate the liver and then pump more chemo to kill cancer cells. Survivor rate has gone from 4 to 23 months. Market potential is about 5-6 billion globally. Stock dropped when a scientist said it wouldn't work but FDA protocol showed results were significant.